Aurobindo’s Unit CuraTeQ Gets EU Nod For Trastuzumab Biosimilar Dazublys

Aurobindo Pharma Ltd. on Wednesday said its step-down subsidiary CuraTeQ Biologics has received marketing authorisation from the European Commission for Dazublys, its biosimilar of cancer drug trastuzumab.

The approval follows a positive opinion issued in April by the European Medicines Agency’s Committee for Medicinal Products for Human Use, the company said in an exchange filing.

Dazublys is the third CuraTeQ biosimilar to be approved by the EMA and the fourth in the European Union overall.